AstraZeneca’s vaccine will be produced in Latin America through a joint agreement with Mexico and Argentina
During their phase three testing, a couple of patients apparently developed problems potentially linked to the formula
It is expected that when the results of these tests are published, they will detail what caused the adverse reaction in these specific cases.
One of the starkest realities about the COVID vaccine is that, from the beginning, it was known that it would not be immediately available to the entire population. In the first months, the available doses will be strategically managed to protect the most vulnerable population first. Among them, older adults, who tend to be more susceptible to dying from the virus. It is for this reason that the report shared by AstraZeneca is such good news.
The laboratory, according to Excelsior, has just published the conclusions of its phase two tests for its anti-COVID vaccine in The Lancet magazine. There, he points out that his formula not only has a degree of effectiveness greater than 90 percent among the young population, between 18 and 55 years old. Also for those who are older, it appears to offer similar protection. The results, while promising, must be confirmed in phase three.
According to the AstraZeneca experts, it was a concern that the vaccine was not as effective in older adults. This, because this population has a weaker immune system, and therefore does not tend to generate defenses with equal ease. Likewise, he warned that his results could offer a not so reliable reality, due to the limitations of his sample. This is because, among the older participants, their average age was 73-74 years.
Positive news for the vaccine, but with a detail
Even with AstraZeneca reserves, the possibility that their formula is also highly effective among older adults is encouraging information. According to Healthline, one of the main problems in countries like the United States (USA) and the United Kingdom, at least at the beginning of the crisis, was infectivity among older adults. As the virus moved with great speed among this population, mortality rates skyrocketed significantly.
At the same time, it is important to remember that these results should be taken with great caution and not jump to conclusions. According to the Washington Post, it is precisely in the testing phases that a vaccine tends to show problems and failures. The later the stage of the investigation, the more likely it is that even a promising candidate will not be as positive as expected. That’s why even AstraZeneca has contextualized its success.
It must also be remembered that the official publication of the results in a journal is not the last step in verifying the effectiveness of a vaccine, drug or treatment. Vox already mentioned it after Pfizer and BioNTech published the preliminary results of their own formula. Press releases or scientific publications, by themselves, do not ensure that a project is effective. The results should be submitted to the analysis of the whole community.
The race between AstraZeneca and its rivals is closed
Of course, not the vaccine from this British laboratory and the University of Oxford have reported high rates of effectiveness. In fact, many of the loudest formulas in recent months have boasted similar preliminary results. Moderna and Pfizer have said their drugs are 95 percent effective in eliciting a response against COVID-19. For its part, Sputnik V has boasted a rate only slightly lower.
It must be emphasized that it is not the only race that is at stake for the development of an anti-COVID vaccine. Different countries and regions of the world also have a particular interest in ensuring fair prices for doses. In this way, they will be able to offer them to their citizens at an adequate cost, even for free. However, each laboratory will set a price that meets its business needs or other economic and political considerations.